Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

被引：18

作者：

Cramer, Paula ^{[1
,2
]}

Fink, Anna-Maria ^{[1
,2
]}

Busch, Raymonde ^{[3
]}

Eichhorst, Barbara ^{[1
,2
]}

Wendtner, Clemens-Martin ^{[4
]}

Pflug, Natali ^{[1
,2
]}

Langerbeins, Petra ^{[1
,2
]}

Bahlo, Jasmin ^{[1
,2
]}

Goede, Valentin ^{[1
,2
]}

Schubert, Friederike ^{[1
,2
]}

Doehner, Hartmut ^{[5
]}

Stilgenbauer, Stephan ^{[5
]}

Dreger, Peter ^{[6
]}

Kneba, Michael ^{[7
]}

Boettcher, Sebastian ^{[7
]}

Mayer, Jiri ^{[2
,8
]}

Hallek, Michael ^{[1
,2
]}

Fischer, Kirsten ^{[1
]}

机构：

[1] Univ Cologne, Dept Internal Med 1, D-50931 Cologne, Germany

[2] Univ Cologne, Ctr Integrated Oncol Cologne Bonn, D-50931 Cologne, Germany

[3] Tech Univ Munich, Inst Med Stat & Epidemiol, D-80290 Munich, Germany

[4] Klinikum Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany

[5] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany

[6] Heidelberg Univ, Dept Med 5, Heidelberg, Germany

[7] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[8] Univ Hosp Brno, Dept Hematooncol, Brno, Czech Republic

来源：

LEUKEMIA & LYMPHOMA | 2013年 / 54卷 / 08期

关键词：

CLL; therapy; chemoimmunotherapy; relapse;

D O I：

10.3109/10428194.2013.796050

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Updated results of the CLL8 trial confirm that the addition of rituximab to chemotherapy with fludarabine and cyclophosphamide (FC) leads to a prolongation of progression-free (PFS) and overall survival (OS) in first-line treatment of physically fit patients. After a median observation time of 47 months, median PFS was 57.9 months for patients treated with FC and rituximab (FCR) and 32.9 months for patients treated with FC alone (hazard ratio 0.56, 95% confidence interval 0.465-0.673; p < 0.001). A total of 232 patients were treated for relapse, among them 91 of 408 (22%) initially treated with FCR and 141 of 409 (35%) initially treated with FC. The drugs most frequently used either alone or in combination were rituximab (52% of all second-line therapies), fludarabine (21%), bendamustine (21%) and alemtuzumab (12%). The regimens chosen for second-line treatment after FC or FCR were heterogeneous, which underlines a need for further trials in order to define treatment recommendations for patients with relapsed chronic lymphocytic leukemia.

引用

页码：1821 / 1822

页数：2

共 50 条

[31] A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, Rituximab combination (FCR) in chronic lymphocytic leukemia (CLL).
Keating, M
Manshouri, T
O'Brien, S
Wierda, W
Kantarjian, H
Washington, L
Lerner, S
Albitar, M
BLOOD, 2002, 100 (11) : 205A - 205A
[32] Impact and predictors of reducing prescribed doses of fludarabine, cyclophosphamide and rituximab (FCR) in frontline treatment of chronic lymphocytic leukemia (CLL)
Kovacs, G.
Bahlo, J.
Kluth, S.
Fink, A. M.
Cramer, P.
von Tresckow, J.
Maurer, C.
Langerbeins, P.
Gross-Opphoff-Mueller, C.
Fischer, K.
Wendtner, C. -M.
Kreuzer, K. -A.
Stilgenbauer, S.
Hallek, M.
Eichhorst, B.
Goede, V.
Oncology Research and Treatment, 2015, 38 : 91 - 91
[33] Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
Tam, Constantine S.
O'Brien, Susan
Plunkett, William
Wierda, William
Ferrajoli, Alessandra
Wang, Xuemei
Do, Kim-Anh
Cortes, Jorge
Khouri, Issa
Kantarjian, Hagop
Lerner, Susan
Keating, Michael J.
BLOOD, 2014, 124 (20) : 3059 - 3064
[34] Oral fludarabine and cyclophosphamide in previously untreated chronic lymphocytic leukemia (CLL): Preliminary data.
Cazin, B
Binet, JL
Divine, M
Lepretre, S
Lederlin, P
Travade, P
Lemaire, G
Guibon, O
BLOOD, 2000, 96 (11) : 515A - 515A
[35] Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab induces a high incidence of complete response in patients with chronic lymphocytic leukemia (CLL).
Lamanna, N
Weiss, MA
Maslak, PG
Gencarelli, AN
Scheinberg, DA
Horgan, D
BLOOD, 2003, 102 (11) : 440A - 440A
[36] Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL)
Obrtlikova, Petra
Jonasova, Anna
Siskova, Magda
Cmunt, Eduard
Berkova, Adela
Karban, Josef
Svackova, Katerina
Trneny, Marek
BLOOD, 2012, 120 (21)
[37] Fludarabine plus cyclophosphamide (FC) and dose intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia (CLL):: Results of two phase II studies (CLL2-protocol) of the german cll study group (GCLLSG).
Hallek, M
Wilhelm, M
Emmerich, B
Döhner, H
Fostitsch, HP
Sezer, O
Herold, M
Knauf, W
Busch, R
Schmitt, B
Wendtner, CM
Kuse, R
Freund, M
Franke, A
Schriever, F
Nerl, C
Thiel, E
Hiddemann, W
Brittinger, G
BLOOD, 1999, 94 (10) : 313A - 313A
[38] Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)
Fink, Anna
Pflug, Natali
Busch, Raymonde
Fingerle-Rowson, Gunter R.
Eichhorst, Barbara
Wendtner, Clemens-Martin
Winkler, Dirk
Buehler, Andreas
Mendila, Myriam
Wenger, Michael
Dohner, Hartmut
Stilgenbauer, Stephan
Hallek, Michael
Fischer, Kirsten
BLOOD, 2010, 116 (21) : 404 - 405
[39] Fludarabine and cyclophosphamide: A highly active and well tolerated regimen for patients with previously untreated chronic lymphocytic leukemia (CLL).
Flinn, IW
Byrd, JC
Morrison, C
Jamison, J
Miller, C
Christie, RJ
Gore, S
Burke, P
Vogelsang, G
Grever, MR
BLOOD, 1998, 92 (10) : 104A - 104A
[40] Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL).
Wierda, W. G.
Kipps, T. J.
Duerig, J.
Griskevicius, L.
Stilgenbauer, S.
Mayer, J.
Gorczyca, M.
Andersen, M.
Nielsen, T.
Russell, C. A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →